BENVIVA Trademark

Trademark Overview


On Monday, May 16, 2022, a trademark application was filed for BENVIVA with the United States Patent and Trademark Office. The USPTO has given the BENVIVA trademark a serial number of 97412560. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 8, 2024. This trademark is owned by Benviva Inc.. The BENVIVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for use in humans for the treatment of bacterial infections, parasitic infections, viral infections, imunocomprimized infections; Biological preparations for human use, namely, biological tissue cultures for treating diseases of the cardiovascular system, diseases of the gastrointestinal system, ocular system, skeletal system, respiratory system, and skin;, namely, disorders of fibrosis and scarring, fibroids, hepatic fibrosis, pulmonary fibrosis, low grade scarring such as, increased fibrosis, keloids, post-surgical scars, wound healing, surgical scarring, fibrosclerosis, scar growth, keloid, fractures; Pharmaceutical and biological preparations for use in humans, namely, gene therapy, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for treatment of genetic disorders, the musculo-skeletal system, namely, connective tissue disease, bone diseases, spinal diseases, rejection of grafts and tran...
benviva

General Information


Serial Number97412560
Word MarkBENVIVA
Filing DateMonday, May 16, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for use in humans for the treatment of bacterial infections, parasitic infections, viral infections, imunocomprimized infections; Biological preparations for human use, namely, biological tissue cultures for treating diseases of the cardiovascular system, diseases of the gastrointestinal system, ocular system, skeletal system, respiratory system, and skin;, namely, disorders of fibrosis and scarring, fibroids, hepatic fibrosis, pulmonary fibrosis, low grade scarring such as, increased fibrosis, keloids, post-surgical scars, wound healing, surgical scarring, fibrosclerosis, scar growth, keloid, fractures; Pharmaceutical and biological preparations for use in humans, namely, gene therapy, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for treatment of genetic disorders, the musculo-skeletal system, namely, connective tissue disease, bone diseases, spinal diseases, rejection of grafts and transplants, and other rare diseases; Pharmaceutical and biological preparations for use in humans for the treatment of central nervous systems diseases, Alzheimer's, Parkinson's, respiratory track diseases, metabolic syndrome, cardiac diseases, skin diseases, cancer, high cholesterol, diabetes, sexually transmitted diseases, autoimmune diseases, multiple sclerosis, free radical oxidation; Pharmaceutical and biological preparations for veterinary medicine for the treatment of bacterial infections, parasitic infections, viral infections, imunocomprimized infections; Biological preparations for veterinary use, namely, biological tissue cultures for treating diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the ocular system, diseases of the musculo-skeletal system, diseases of the respiratory system, and skin, namely, disorders of fibrosis and scarring, fibroids, hepatic fibrosis, pulmonary fibrosis, low grade scarring such as, increased fibrosis, keloids, post-surgical scars, wound healing, surgical scarring, fibrosclerosis, scar growth, keloid; Pharmaceutical and biological preparations for veterinary medicine, namely, gene therapy, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for treatment of genetic disorders, the musculo-skeletal system, namely, connective tissue disease, bone diseases, spinal diseases, rejection of grafts and transplants, and other rare diseases; Pharmaceutical and biological preparations for veterinary medicine for the treatment of central nervous systems diseases, Alzheimer's, Parkinson's,respiratory track diseases, metabolic syndrome, cardiac diseases, skin diseases, cancer, high cholesterol, diabetes, sexually transmitted diseases, autoimmune diseases, multiple sclerosis, free radical oxidation. Pharmaceutical and biological herbicides, pesticides, fungicides for agricultural use, and domestic use
Translation of Words in MarkThe English translation of Benviva in the mark is Sunlife potentially in esperanto.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, May 23, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBenviva Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001

Party NameBenviva Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001

Trademark Events


Event DateEvent Description
Monday, January 8, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 8, 2024ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 4, 2023ASSIGNED TO EXAMINER
Monday, May 23, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 19, 2022NEW APPLICATION ENTERED